Fig. 5

Telomere attrition in COVID-19 patients. Telomere attrition acceleration measured via the DNAm TL surrogate marker (a–f) in the peripheral blood of COVID-19 patients. Telomere attrition acceleration in a COVID-19 patients at baseline (T1) versus controls b in surviving COVID-19 patients at inclusion versus the last recorded measurement at the end of Follow-Up (FU) c) in deceased COVID-19 patients at inclusion versus end of FU d in survived versus deceased patients at T1and e at the end of FU. f Dynamic change in telomere attrition acceleration between the end of follow-up and inclusion. The y-axis denotes telomere attrition acceleration apart from panel (f), representing a change in telomere attrition acceleration between the end of FU and inclusion. p value is shown above the corresponding line. In the box plots, the lower and upper hinges indicate the 25th and 75th percentiles and the black line within the box represents the median. ns: non-significant